Please assess the completion status of the following clinical trial:

Trial Title: Morphine in Moderate Obstructive Sleep Apnoea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Patients with diagnosis of moderate or severeOSA at screening, diagnosed by nocturnal oximetry, rPSG or PSG (defined as AHI or ODI of 15-50 events/hour) established on Continuous Positive Airway Pressure (CPAP)~3. Patients established on CPAP with confirmed moderate OSA (AHI 15-29 events/hr) 6 nights after withdrawal of CPAP (confirmed at baseline rPSG)~4. Patients diagnosed with moderate OSA by rPSG or PSG, naïve to CPAP treatment~Exclusion Criteria:~* Inability to give informed consent or comply with the protocol~* Current, clinically significant acute respiratory tract infection (at screening and at study visit)~* Chronic respiratory disease (other than OSA), symptomatic ischemic heart disease~* Pregnancy or suspected pregnancy/breast feeding~* Current or recent (within last week of entering the trial and for the duration fo the trial) use of gabapentin, pregabalin, melatonin, mirtazapine, benzodiazepines, barbiturates, sodium oxybate, ramelteon, Z-drugs and opiates/opioids~* Monoamine oxidase inhibitors (MAOIs), linezolid taken within two weeks of participation in the trial~* A known allergy to the investigational medicinal product (IMP) or non investigational medicinal product(s) (NIMP)(s)~* Patients with an inadequate command of English and such that an interpreter would be required overnight~* Change in weight of greater than 5% since the baseline rPSG~* Vital signs recordings (oxygen saturations, blood pressure, pulse rate) that in the clinician's opinion deem the patient unsafe to participate in the trial~* Clinician deems the patient unsafe to participate in the trial (e.g. severely sleepy patients who cannot withdraw from CPAP)~* CPAP intolerant/poor responder~* History of drug abuse (oral and intravenous) including: alcohol, substituted amphetamines, barbiturates, benzodiazepines, cocaine, methaqualone, cannabis and opioids~* A drop of oxygen saturations below 85% continuously for longer than five minutes during the baseline rPSG~* Professional driver

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Morphine sulphate (Type: EXPERIMENTAL): Participants will be given a first dose of morphine sulphate (intravenously) before bedtime and a second dose four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness

Based on this trial design, predict the completion outcome and termination type (if applicable).